Although the mechanisms of acquired resistance of EGFR‐mutant NSCLC to EGFR‐TKIs have been identified,4 little is known about the transfer mechanism between EGFR‐TKI–resistant cells and sensitive cells and how this transmission affect drug response needs to be further elucidated. This evidence concerns the gene EGFR and non-small cell lung carcinoma.